Cancer Screening Company Nucleix Raises 2.5 Million Euros

Founded in 2008, Nucleix develops non-invasive, DNA methylation-based cancer screening tests. Methylation is the process in which methyl groups are added to DNA molecules. It can change the way genes are expressed by cancer cells. Nucleix has received a CE Mark (European approval) for its urine-based bladder cancer test, and has two other blood-based tests in its pipeline, one for cancer and one for multiple types of cancer.

Blood test (illustration) Photo: Shutterstock

Previously, Nucleix Raised $ 11.4 million in equity funding according to Pitchbook, from investors including Herzliya based healthcare investment firm Orbimed Israel Partners Ltd. and Aurum Ventures MKI.

Lung cancer is the second most common type of cancer, but the leading cause of cancer mortality, according to the American Cancer Society. As with most diseases, early increases increases the chances of survival.

Nucleix expects to begin extensive clinical trials for its lung cancer detection test at the beginning of 2019, in Europe and in the US, said Nucleix CEO Opher Shapira in a statement.